Enanta Pharmaceuticals | ENTA - Passività Correnti





Passività Correnti Cambiamento Data
AbbVie USD 41.64B 458M 2026-06
Amgen USD 25.5B 547M 2026-06
Anika Therapeutics USD 22.15M 1.18M 2026-06
Arrowhead Research USD 283.35M 11.87M 2026-06
AstraZeneca USD 31.55B 1.02B 2026-06
BioCryst Pharmaceuticals USD 208.85M 13.46M 2026-06
Biogen USD 3.92B 918.2M 2026-06
Bristol-Myers Squibb USD 18.66B 499M 2026-06
Enanta Pharmaceuticals USD 44.73M 3.83M 2025-12
Gilead Sciences USD 11.02B 1.54B 2026-06
GlaxoSmithKline GBP 21.53B 895M 2026-06
Halozyme Therapeutics USD 344.44M 18.77M 2026-06
Heron Therapeutics USD 92.14M 1.63M 2026-06
Immunic USD 38.36M 7.74M 2026-03
Incyte USD 1.31B 177.55M 2026-06
Insmed USD 438.74M 77.74M 2026-06
Ionis Pharmaceuticals USD 315.64M 401.36M 2026-06
J&J USD 54.9B 2.82B 2026-06
Karyopharm Therapeutics USD 117.3M 25.24M 2026-03
Ligand Pharmaceuticals USD 46.74M 6.07M 2026-06
Merck USD 27.73B 786M 2026-06
Neurocrine Biosciences USD 874.5M 42.8M 2026-06
Novartis USD 31.75B 374M 2026-06
Novavax USD 330.57M 11.89M 2026-06
Pfizer USD 32.65B 1.7B 2026-06
PTC Therapeutics USD 771.07M 152.54M 2026-06
Roche Holding CHF 28.85B 846M 2026-06
Sarepta Therapeutics USD 502.91M 3.74M 2026-06
Vertex Pharmaceuticals USD 3.94B 57.3M 2026-06